BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for ...

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best healthcare stocks with the highest upside. Ocular Therapeutix Inc.

Ocular Therapeutix to receive $12 million upfront fee and development and commercialization milestones and other payments of up to $91 million plus additional royalties on future product sales BEDFORD ...

About OTX-TIC (travoprost implant) for Intracameral Use OTX-TIC is a bioresorbable intracameral implant containing micronized travoprost that is injected into the anterior chamber of the eye and is ...

DEXTENZA® Net Product Revenue in Third Quarter of $5.4 Million, a 280% Increase from the Prior Quarter Reported Topline Phase 1 Results and Recently Initiated Phase 2 Clinical Trial of OTX-CSI for the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Subjects treated with OTX-TIC demonstrated a mean ...

Ocular Therapeutix ( ($OCUL) ) just unveiled an announcement. On September 30, 2025, Ocular Therapeutix announced the pricing of an underwritten ...

Dextenza ® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year ...

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the best biotech stocks with high potential. On October 3, Piper Sandler ...

Shares have risen by 57% since my initial recommendation and by 13% since my July update. I provide a recap of the bullish thesis and recent events. A cash influx in the near term appears necessary, ...

Exact medical conference presentation times may be subject to change.